Ken Griffin Invitae Corp Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.72 $7,770 - $13,320	-18,500 Reduced 5.08%	345,800 $217,000
Q3 2023 Nov 14, 2023	BUY	$0.6 - $1.53 $82,200 - $209,610	137,000 Added 60.27%	364,300 $218,000
Q2 2023 Aug 14, 2023	SELL	$1.05 - $1.63 $118,125 - $183,375	-112,500 Reduced 33.11%	227,300 $256,000
Q1 2023 May 15, 2023	BUY	$1.2 - $2.73 $133,200 - $303,030	111,000 Added 48.51%	339,800 $458,000
Q4 2022 Feb 14, 2023	SELL	$1.71 - $3.61 $371,241 - $783,731	-217,100 Reduced 48.69%	228,800 $425,000

Q3 2022 Nov 14, 2022	BUY	$1.9 - $8.63 $170,430 - $774,111	89,700 Added 25.18%	445,900 $1.1 Million

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.